# A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients

> **NCT01266005** · PHASE4 · TERMINATED · sponsor: **Bukwang Pharmaceutical** · enrollment: 75 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Clevudine
- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT01266005
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2013-08
- **Final completion:** 2014-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2014-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266005, "A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01266005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*